Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?-Reference-Cited by-同舟云学术

Is still there a role for IL-2 for solid tumors other than melanoma or renal cancer?

Published:2017-01 Issue:1 Volume:9 Page:25-32
ISSN:1750-743X
Container-title:Immunotherapy
language:en
Short-container-title:Immunotherapy

Author:

Roviello Giandomenico¹²,Zanotti Laura²,Correale Pierpaolo³,Gobbi Angela²,Wigfield Simon⁴,Guglielmi Alessandra⁵,Pacifico Chiara³,Generali Daniele²⁶

Affiliation:

1. Department of Molecular & Translational Medicine, University of Brescia, 25123 Brescia, Italy

2. Unit of Molecular Therapy & Pharmacogenomics, ASST Cremona, Viale Concordia 1, 26100 Cremona, Italy

3. Unit of Radiotherapy, Department of Medical, Surgical Sciences & Neurosciences, Siena University, Viale Bracci 11, 53100 Siena, Italy

4. Department of Oncology, Molecular Oncology Laboratories, The Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital Headley Way, Headington, Oxford, OX3 9DS, UK

5. Unit of medical oncology, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy

6. Department of Medical, Surgery & Health Sciences, University of Trieste, Piazza Ospitale 1, 34129 Trieste, Italy

Abstract

Aim: IL-2 is one of the first immunomodulating cytokines to be tested in the treatment of cancer patients. The effects of this agent in the treatment of solid tumors other than renal cancer and melanoma are poorly understood. Materials & methods: We have carried out a meta-analysis of randomized studies. We fixed the response rate as the primary outcome. Results: The pooled risk ratio for an objective response with IL-2 plus chemotherapy versus chemotherapy alone was 1.43 (95% CI: 1.12–1.81; p = 0.004), in favor of colorectal cancer. Conclusion: Further investigation in the treatment of patients with colorectal cancer or other solid malignancies with IL-2 is required, alone or in combination with chemotherapy.

Publisher

Future Medicine Ltd

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.futuremedicine.com/doi/pdf/10.2217/imt-2016-0107

Reference37 articles.

1. Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

2. Overview of interleukin-2 function, production and clinical applications

3. Interleukin-2: Inception, Impact, and Implications

4. Cancer Immunotherapy: Past Progress and Future Directions

5. Treatment of 283 Consecutive Patients With Metastatic Melanoma or Renal Cell Cancer Using High-Dose Bolus Interleukin 2

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunotherapy in Genitourinary Malignancy: Evolution in Revolution or Revolution in Evolution;Cancer Immunotherapies;2022

2. Cytokine Profiling of End Stage Cancer Patients Treated with Immunotherapy;Vaccines;2021-03-08

3. Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas;PLOS ONE;2020-04-16

4. Genetic Variants of the IL2 Gene Related to Risk and Survival in Patients With Colorectal Cancer;Anticancer Research;2019-09

5. Optimal primary end point in Phase II trials of immune checkpoint inhibitors for advanced solid cancers: an evolving issue;Immunotherapy;2019-04